Background. The treatment of differentiated thyroid cancer refractory to radioactive iodine (RAI) had been hampered by few effective therapies. Recently, tyrosine kinase inhibitors (TKIs) have shown activity in this disease. Clinical guidance on the use of these agents in RAI-refractory thyroid cancer is warranted. Materials and Methods. Molecular mutations found in RAIrefractory thyroid cancer are summarized. Recent phase II and III clinical trial data for TKIs axitinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitinib, and vandetinib are reviewed including efficacy and side effect profiles. Molecular targets and potencies of these agents are compared. Inhibitors of BRAF, mammalian target of rapamycin, and MEK are considered.
INTRODUCTION
The incidence of thyroid cancer in the U.S. is 12.9 per 100,000 per year, with a lifetime risk of 1.1%, making it the ninth most common malignancy in the U.S. [1] . The incidence rate has been climbing steadily since the 1990s at a rate of 6.5% yearly, although 5-year relative survival has held steady at ∼95%. It is thought that overdiagnosis of previously clinically occult malignancy only partially accounts for the rising incidence [2] . The increasing incidence makes thyroid cancer the most rapidly increasing cancer in the U.S. It affects women more than men at a 3:1 ratio, most commonly in the fifth decade of life. It is estimated that approximately 500,000 persons in the U.S. are living with thyroid cancer [1] .
Differentiated thyroid cancer (DTC) subtypes (papillary, follicular, Hurthle cell) make up ∼93% of all thyroid cancers, with medullary and anaplastic subtypes making up 4% and 2%, respectively [2] . Management of DTC typically consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, followed by TSH suppression [3] . Only 3% of patients have metastasis at the time of presentation. Patients with distant metastatic disease at presentation have a 50% rate of 5-year survival mainly because of the sensitivity of metastatic disease to RAI therapy [1, 4] . Age at diagnosis has a strong effect on survival; patients aged ,51 years have a .90% rate of 10-year survival, even with distant disease detected at time of diagnosis [5] . It is estimated that 20% of patients with locoregional disease at presentation will develop distant metastasis at some point in their lifetimes [6] . Distant metastasis most commonly occurs in lungs, followed by bones, and less commonly in other sites. In the metastatic setting, serial treatments with RAI can render ∼40% of patients free of disease over the course of 5 years, with a recurrence rate of only 7% [7] . However, patients whose tumors fail to respond adequately to RAI have a mere 19% rate of 5-year survival.
A dose-response relationship exists between the amount of radioactive iodine administered and the risk of second primary malignancies, including solid tumors and leukemias. Based on these and other risks (pulmonary fibrosis, xerostomia, lacrimal complications), it has been suggested that repeated RAI courses can be administered safely to a cumulative dose of 600 mCi, after which further RAI should be administered only on an individual basis with careful consideration of risks and benefits [7] [8] [9] [10] . The repeated use of iodine 131 ( 131 I) should be restricted to patients who continue to respond to it [11] .
There is no consensus definition of what constitutes RAIrefractory thyroid cancer. Clinical criteria endorsed by the American Thyroid Association (ATA) thyroid cancer guidelines point to indicators of poor response to RAI including lack of RAI avidity on diagnostic RAI scan and suboptimal prior response duration to RAI [12] . 131 I responses are also more likely to be poor in older patients (aged .40 years) and in patients with large tumor burden, poorly differentiated tumors, or lesions that are fluorodeoxyglucose (FDG) avid on position emission tomography (PET) [6, 13] .
MATERIALS AND METHODS
Databases queried include PubMed and Embase, and conference proceedings of European Society for Medical Oncology, American Society for Clinical Oncology, American Association for Cancer Research, and ATA. Search terms were differentiated thyroid cancer, follicular thyroid cancer, papillary thyroid cancer, axitinib, pazopanib, cediranib, lenvatinib, sorafenib, sunitinib, vandetanib, selumetinib, gefitinib, motesanib, vemurafenib, dabrafenib, everolimus, temsirolimus, vatalanib, bevacizumab, regorafenib, nintedanib, and cabozantinib. Databases were queried with dates from 2005 to March 2014. A second search was performed using dates from 2009 to June 2014. The ClinicalTrials.gov website was also searched with the above terms. Only publications in English involving human subjects or human tissues were considered. Both abstracts and articles were considered.
MUTATIONAL SPECTRUM OF DTC
In theory, an understanding of the mutations prevalent in differentiated thyroid cancer could lead to the selection of targeted agents for this disease.The mutations associated with DTC have been extensively reviewed recently [14] . The most common known genetic abnormality in DTC is the BRAF V600E mutation, which is present in approximately 45% of papillary thyroid cancer (PTC) but is less common in follicular thyroid cancer (FTC) [15] [16] [17] [18] . In contrast, RAS mutations are more common in FTC, with mutations in HRAS, NRAS, or KRAS detectable in approximately 40% of FTC [19] [20] [21] [22] [23] [24] [25] [26] [27] . Translocations involving the RET gene, so-called RET-PTC translocation, are present in 10%-87% of PTCs (median: ∼30%) [28] [29] [30] . These translocations juxtapose the RET gene with a number of different translocation partners of which 10 have been characterized thus far, the most common being RET-PTC1
and RET-PTC3, in which RET is fused to the CCDC6 and NCPA4 genes, respectively. Other mutations detected less frequently include mutations in PIK3CA/B [19, 31, 32] , IDH1 [33, 34] , EGFR [35], and PAX8-PPARg translocation [36] . NDUFAB/GRIM19 mutations are found in 15% of Hurthle cell thyroid cancers [37] .
Numerous studies have highlighted that mutations affecting the MAPK pathway are often mutually exclusive in DTC. Soares et al. showed BRAF mutations in 46% of PTC and 0% of FTC [38] . RAS mutations were found in 33% of FTC and 7% of PTC. None of the PTCs with RAS mutations had a coexisting BRAF mutation. Furthermore, 18% of PTCs had RET-PTC mutations, all of which were negative for BRAF mutations. Similarly, Kimura et al. analyzed mutations in PTC, showing BRAF in 33%, RAS in 16%, and RET-PTC in 16%, all of which were mutually exclusive with each other [39] . This could indicate either similar function of all three classes of mutation or synthetic lethality of the mutations. It is unknown why RAS mutations tend to be more prevalent in FTC, whereas PTC is more likely to harbor BRAF and RET-PTC mutations.
There has been a more recent appreciation of the prevalence of PIK3CA/B mutations in DTC. The PIK3CA/B genes can undergo amplification events or activating mutations, both of which likely contribute to oncogenesis. PIK3C amplification is more prevalent than mutation. In FTC samples, 6% had PIK3CA mutations, whereas 45% had PIK3CA amplification and 45% had PIK3CB amplification [19] . Similarly, Abubaker et al. found PIK3CA copy number gain in 53% of PTC, with a PIK3CA mutation rate of only 1.9% [31] . PIK3CA mutations tend to be mutually exclusive with amplification events and mutually exclusive with RAS and PTEN mutations but not with BRAF mutations [20, 21] .
Transcriptional activation of VEGFR has been shown to be a downstream effect of activation of the nuclear factor-kB and RAS/RAF/ERK signaling cascades [40] . This has led to the targeting of VEGFR, specifically, to interfere with oncogenic signaling in DTC.
MECHANISM OF ACTION OF AGENTS STUDIED IN DTC
All TKIs available to date inhibit multiple kinases. The TKIs shown to have activity in RAI-refractory DTC (RAI-R-DTC) share a number of common targets but also have important differences in their target spectrums ( Table 1 ). The shared targets include multiple VEGFRs and the related PDGFRs and FGFRs as well as RET. Axitinib has the highest affinity for VEGFRs with subnanomolar half-maximal inhibitory concentration (IC 50 ). All other TKIs with activity against DTC bind VEGFRs with IC 50 ranging from 1 to 20 nM and high affinity, with the exception of vandetanib. TKIs that target RET include motesanib, pazopanib, sorafenib, sunitinib, and vandetanib; sorafenib has the lowest IC 50 (2 nM).The most pleomorphic of the agents is sunitinib, which targets 38 kinases with submicromolar IC 50 . Sorafenib is the only TKI with some inhibitory activity to BRAF (IC 50 : 290 nM).
Everolimus and temsirolimus have specificity for mammalian target of rapamycin (mTOR); everolimus is much more potent. The selective BRAF inhibitors dabrafenib and vemurafenib inhibit both native and V600E mutant BRAF; however, both agents inhibit the mutant enzyme at lower IC 50 . Selumetinib is a selective MEK inhibitor. TKIs produce progression-free survival of ∼1 year with a range of 7.7-19.6 months. The most likely outcome of treatment with a tyrosine kinase inhibitor is stable disease.
Complete responses (CRs) are rare. We have also learned that EGFR inhibition with gefitinib generally is not useful and perhaps detrimental because there were no PRs by RECIST, and the percentage of patients who achieved stable disease was lower than that achieved in the placebo control arm of other studies. Nevertheless, 36% of patients achieved tumor shrinkage with gefitinib [65] .
The randomized phase II clinical trial with vandetinib, which stratified patients based on histology, seemed to suggest that papillary histology had a more favorable response rate to TKI than follicular or poorly differentiated thyroid cancer [79] , but data across TKI trials to date are inadequate to state conclusively that histology is a predictor of response.The phase III trials of sorafenib and lenvatinib did not show that histological subtypes were predictors for PFS, despite the confirmation that histological type was prognostic [81, 82] .
Two phase II trials evaluated axitinib with total enrollment of 112 patients ( Sherman et al. evaluated lenvatinib in a phase II trial that enrolled 58 patients with DTC (including medullary) who had progressive disease by RECIST within the previous 12 months ( Table 2) . DTCs had to be RAI refractory as defined by lack of RAI uptake, progression despite RAI uptake, or .600 mCi of RAI administered with the last dose within the prior 6 months. This trial demonstrated median PFS of 12.6 months with a 50% partial response rate. OS was not reported. In addition, 29% of patients experienced grade 3 toxicity, and 9% had grade 4 toxicity.
The recently reported preliminary results of the SELECTphase III randomized controlled trial comparing lenvatinib and placebo were impressive (Table 3 ). This study enrolled 392 patients with documented disease progression in the prior 13 months.The trial met its primary endpoint of PFS; median PFS on lenvatinib was 18.3 months, compared with 3.6 months on placebo. Median OS, a secondary endpoint, was not reached, although crossover was allowed after progression, and 83% crossed over.There were four complete responses to lenvatinib (none on placebo). Partial responsesbyRECISTwereseenin63.2%onlenvatiniband1.5%on placebo.The most common grade $3 treatment-related adverse events were hypertension, proteinuria, weight loss, diarrhea, and decreased appetite. Of particular interest is that, of the 25% of the patients who had received a TKI prior to enrollment, response rates and PFS in this subgroup were indistinguishable from those of the TKI-naïve patients.
The use of sorafenib in RAI-R-DTC has been studied in six clinical trials, including one phase III trial (Tables 2, 3 ). The phase III DECISION trial entry criteria required RAI-R-DTC, evidence of disease progression in the 14 months prior to entry, and patients who were TKI naive.The trial demonstrated median PFS of 10.8 months in patients randomized to sorafenib versus 5.8 months for placebo, thus meeting its primary endpoint [81] . The most likely outcome was stable disease for .6 months in 42% of sorafenib-treated patients; 33% of placebo controls had SD .6 months. Twelve percent had PR to sorafenib by RECIST; there was only a rare PR on placebo. Common Terminology Criteria for Adverse Events (CTCAE) grade 3 events were experienced by 53% of sorafenibtreated patients compared with 23% of controls. CTCAE grade 4 events were experienced by 12% in the sorafenib arm and 7% of controls. It should be noted that this trial allowed for crossover after progression. Schlumberger et al. reported the results of quality-of-life analyses of patients treated in the DECISION trial. These analyses showed a small but significant detriment to quality of life in the sorafenib-treated arm compared with placebo [83] .
The other trials with sorafenib enrolled between 9 and 56 patients in phase II studies ( Table 2) . One phase II trial enrolled 41 patients with metastatic PTC (not necessarily refractory to RAI) [71] . By RECIST, 15% had PR and 23% had SD .6 months. Median PFS was 15 months. Of 18 patients with evaluable thyroglobulin levels, 78% had a decline by .25%. Similarly, waterfall plots showed 87% with either SD or PR evinced by tumor shrinkage.
The remaining four trials with sorafenib showed median PFS ranging from 9 to 19.6 months, with stable disease the most likely outcome, ranging from 34% to 65%; partial response was 23%-25% by RECIST (Table 2 ). One study specifically evaluated patients with RAI-refractory pulmonary metastases from PTC, as ©AlphaMed Press 2015
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TKIs in RAI-Refractory Thyroid Cancer CME defined by lack of uptake on RAI-uptake scan [72] . Nine patients were enrolled; by RECIST, 33% had PR and 44% had SD with median PFS of 42 weeks. Waterfall plot analysis was not included, but a mean 60% decrease in thyroglobulin levels was reported.
One trial evaluated motesanib in 93 DTC patients with radiographic evidence of progressive disease by RECIST in the prior 6 months and lesions that were not amenable to surgery or radiation or that were resistant to RAI [67] ( Table 2 ). The trial demonstrated progression-free survival of ∼9.3 months, with Pazopanib has been evaluated in a phase II trial of 39 patients with RAI-R-DTC required to have radiographic evidence of progression by RECISTwithin 6 months of trial entry [68] .This trial demonstrated median PFS of 11.7 months, with 49% PR by RECIST 1.0 ( Table 2) .Waterfall plots showed only 2 patients with tumor growth as the best response; similarly, only 1 of 32 patients with evaluable thyroglobulin levels experienced an increase in thyroglobulin during treatment. Fifty-seven percent experienced grade 3 toxicity. Grade 4 toxicity was uncommon; however, two patients died during the trial of myocardial infarction and bowel perforation, both of which are associated with VEGF inhibition.
Sunitinib has been evaluated in two clinical trials that were both phase II ( Table 2 ). Carr et al. enrolled 35 patients with FDG-avid, RAI-R-DTC and 7 patients with medullary thyroid cancer [77] . By RECIST, there was 1 CR, 28% had PR, and 46% had SD, and median time to progression was 12.8 months. Of 33 evaluable patients, 79% had tumor shrinkage, shown by waterfall plot analysis. Median OS was not reached. Response by PET, as measured by change in standardized uptake value, was also assessed and found to be modest (median change of 210% and 213.9% in patients with PR and SD, respectively). The second trial required patients to have RAI-R-DTC as shown by progression despite treatment with RAI or contraindication to RAI and evidence of radiological or biochemical progression in the prior 6 months [78] . SD was the most common response in 68%, whereas 13% had PR by RECIST. In both trials, toxicities were common, with 43%-53% experiencing at least CTCAE grade 3 toxicity.
Two drugs approved for medullary thyroid cancer, vandetanib and cabozantinib, are being explored in RAI-R-DTC. One randomized phase II trial evaluated vandetinib against a placebo control [79] (Table 2 ). Patients were required to have progression after RAI or have lesions without RAI uptake. Median PFS (the primary endpoint) was 11.1 months in the vandetinib armversus5.9 monthsinthe placebo controlarm.There were 38 grade 3 toxicities. Crossover to vandetanib after progression on placebo was allowed; no difference in OS was observed. Independent central review by RECIST showed only 1 PR in the vandetanib-treated group; however, by waterfall plot, 54% of vandetanib-treated patients had lesions shrink, whereas this occurred for 27% of placebo-treated patients. Disease control (CR plus PR plus SD) was confirmed by independent review to favor vandetanib (56%) versus placebo (26%).
No data are available from phase II/III trials on cabozantinib; however, 15 patients with metastatic RAI-R-DTC who had progressed on standard therapies and had measurable disease were treated with cabozantinib in a phase I study looking at pharmacokinetic interactions with rosiglitazone, a CYP2C8 substrate [84] . Patients had been treated previously with a median of two prior regimens. By modified RECIST, 53% had PR and 40% had SD. Tumor shrinkage was noted in all patients that had at least one postbaseline scan (range: 29 to 255%). Median PFS and OS were not reached.
There are a handful of published experiences with the selective BRAF inhibitor vemurafenib in treating BRAF V600E mutant DTC. One publication detailed three patients that were enrolled in the initial expanded dose-escalation phase I trial of vemurafenib [85] . One patient had PR by RECIST, and the other two had stable disease, although shrinkage of target lesions in both patients was noted, by 9% and 16%. Time to progression was 11.7 months in the patient with PR and 13.2 and 11.4 months in the other two patients, respectively.
Dadu et al. reported a case series of 12 patients with BRAF V600E mutant PTC treated with vemurafenib outside of a clinical trial [86] . They found 25% had PR by RECIST and 75% had SD, of which 5 patients had a minor response, defined by shrinkage of target lesions by 10%-29%. Grade 3-4 CTCAEs included elevated lipase (1 patient), photosensitivity (2 patients), and hand-foot syndrome (HFS; 1 patient).
At the European Cancer Congress 2013, Brose et al. reported the results of a phase II trial in which 56 patients with RAI-refractory PTC with BRAF V600E mutations were treated with vemurafenib; of those, 25 had been treated previously with another TKI [80]. The PR rate by RECIST was 35% in TKInative patients and resulted in 15.6-month PFS. Patients who had been treated previously with a TKI had a 26% PR rate and PFS of 6.8 months. Common AEs included rash, fatigue, weight loss, and hyperbilirubinemia.
The first-in-human phase I study of dabrafenib included 14 patients that had thyroid cancers with BRAF V600E mutations [87] , 13 of which had previously received RAI and 9 of which had not received any systemic treatments apart from RAI. There were four partial responses (29%), and 64% had at least a 10% decrease in tumor size by RECIST. The median PFS was 11.3 months. There was one grade 4 elevated lipase. Grade 3 toxicities included elevated amylase, fatigue, febrile neutropenia, and cutaneous squamous cell carcinoma. One phase II study evaluated everolimus in patients with progressive, locally advanced, or RAI-refractory thyroid cancer of any histology, including 28 patients with differentiated subtypes [88] . Responses were measured by RECIST 1.1. Of the patients with DTC, there were only two responses; however, 71% had tumor shrinkage, shown by waterfall plot. Median PFS was 10 months. Adverse events were as expected based on previous experience with everolimus, with grade 3 mucositis and diarrhea in 15% and 10%, respectively, of all patients.There was one grade 4 pneumonitis.
ONGOING CLINICAL TRIALS
Seventeen ongoing trials are currently listed in the Clinical-Trials.gov database, evaluating 12 drugs including cediranib, lenalidomide, cabozantinib, dabrafenib, trametinib, everolimus, lenvatinib, pazopanib, selumetinib, sunitinib, vandetinib, and vemurafenib (Table 4 ). Three trials are randomized controlled trials, and two are randomized against a placebo control (lenvatinib and vandetinib). The cediranib trial uses randomization with or without lenalidomide. All of these trials have either PFS or response rate as the primary endpoint. Some address overall survival as a secondary endpoint.
SELECTION OF AGENTS BASED ON TUMOR MUTATIONS
Substantial work has aimed to understand whether prospective analysis of genetic mutations in thyroid cancers can dictate selection of targeted agents; however, outcomes of these analyses have not led to robust selection criteria. Substantial work has aimed to understand whether prospective analysis of genetic mutations in thyroid cancers can dictate selection of targeted agents; however, outcomes of these analyses have not led to robust selection criteria.
A retrospective analysis of sequencing from formalin-fixed paraffin-embedded tumors of 18 patients treated with axitinib showed 22% had BRAF V600E mutations, 11% had KRAS mutations, 11% had HRAS mutations, and 1 sample had PIK3CA mutation [110] .There was no correlation of the mutations with response to axitinib, although the sample size was small.
A similar study evaluated BRAF and RAS mutations in patients in the DECISION trial who were treated with sorafenib; [111] . In this study, neither BRAF nor RAS mutation predicted response to sorafenib, even though sorafenib inhibits BRAF directly, albeit weakly (Table 1) . RAS mutation was associated with worse PFS compared with tumors with wild-type RAS. In contrast, BRAF mutation was associated with better PFS compared with patients lacking a BRAF mutation. In a separate study, papillary thyroid cancer cell lines made resistant to pazopanib in culture acquired a KRAS G13V mutation, and this was associated with more aggressive xenograft growth in animal models, further supporting a possible role for KRAS mutation driving a more aggressive disease course [112] . At the 2012 ASCO annual meeting, Ball et al. reported a retrospective analysis of RAS and BRAF mutations in 58 patients treated with lenvatinib, in which cytokine and angiogenic factors were also measured [113] . Results suggested that a combination of serum cytokine levels and mutation status could predict response to lenvatinib, although no external validation of this data set has been performed to date.
ADVERSE EVENTS AND TOXICITY
Clinical experience gleaned from using bevacizumab has taught us that the toxicity associated with VEGFR inhibition includes hypertension, proteinuria, delayed wound healing, bleeding, gastrointestinal (GI)perforation, fistulas, andthrombosis. Some, but not all, of the typical VEGFR inhibition adverse events have been noted with use of TKIs in RAI-R-DTC trials. Many of the agents have been approved by the U.S. Food and Drug Administration (FDA) for other indications and have existing adverse event data, including pazopanib, axitinib, sunitinib, sorafenib, vandetanib, vemurafenib, and dabrafenib. We have highlighted the most prevalent and important toxicities for each drug, as culled from trials in RAI-R-DTC (Table 5) , and drawn parallels to existing AE data, as relevant.
Gastrointestinal side effects including anorexia, nausea, vomiting, stomatitis, and diarrhea are pervasive with these compoundsand are the most likely side-effectclass.Fortunately, grade 3 diarrhea affected ,10% of patients. Weight loss affected a large proportion of patients with most agents (range: 24%-77%), with the exception of sunitinib and vandetanib, which did not report any weight loss.Tracheoesophageal fistula is a rare complication of antiangiogenic TKI therapy; patients with large invasive neck masses or prior neck radiation may be particularly at risk [116] .
Fatigue is a pervasive side effect associated with all of these agents. It affects roughly 50% of treated patients, usually as grade 1 or 2.
Hypertension is associated with antiangiogenic TKIs and can be considered a marker of VEGF inhibition. Grade 3 hypertension ranged from 0%-25% in thyroid cancer trials, but any grade affected ∼40%-60% of patients in these trials. It is generally managed with antihypertensive agents, although dose adjustments may be necessary. Adequate blood pressure control should be achieved prior to initiating TKI therapy.
Proteinuria is seen with axitinib, lenvatinib, and pazopanib but was not observed or recorded in DTC trials of motesanib, sorafenib, sunitinib, or vandetanib. Only ∼5% of patients experience high-grade proteinuria. Sunitinib and sorafenib have both been associated with proteinuria and, rarely, with nephrotic syndrome in other clinical settings [117] . Proteinuria was also seen in MTC trials of vandetanib.
To date, significant rates of venothromboembolism or arterial thrombosis have not been observed in RAI-R-DTC patients treated with these agents. Sorafenib has been associated with increased risk of cardiac ischemia or infarction in a small percentage of patients (2.7%-2.9% vs. 0.4-1.3% of placebo controls) in trials conducted in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC); therefore, the extent to which the underlying disease versus the TKI influences thrombosis risk is unclear.
Hemorrhage has been reported with certain agents. One of the sunitinib trials reported a 14% rate of GI bleeding, including one grade 5 event [77] . Motesanib had 14% rate of hemorrhage including 4% grade $3. Only one of the eight DTC sorafenib trials reported hemorrhage as an adverse event. Sorafenib was associated with an increased risk of hemorrhage in the RCC clinical trials but not in HCC trials, suggesting that patient-or disease-specific factors may play a role. Pazopanib had a 16% rate of epistaxis, none grade $3.
Dermatologic toxicity, especially HFS, has been reported commonly with axitinib, sorafenib, and sunitinib but is especially prominent with sorafenib and can be dose limiting. The sorafenib package insert details suggested dose adjustments for HFS. Alopecia is observed with axitinib, pazopanib, and sorafenib in $50% of patients. Pazopanib causes skin and hair hypopigmentation in 76% of patients. Interestingly, this toxicity is associated with c-kit inhibition and may also be seen with sunitinib [118] and other agents.
Although not evident in the thyroid cancer data set thus far, the FDA prescribing instructions for pazopanib in renal cell carcinoma indicate that hepatotoxicity can be severe and fatal with this agent. Specific guidelines exist for liver function test (LFT) monitoring, and dose adjustments based on LFT levels available in the package insert. In RCC trials, 14% had grade 2 elevations in transaminases and 4% had grade 3 elevations. Similarly, sunitinib carries a black box warning for hepatotoxicity; in clinical trials outside of thyroid cancer, 0.3% suffered liver failure.
Vandetanib carries a black box warning for QTc prolongation, torsade de pointes, and sudden death and requires a risk-reduction prescriber program to administer the drug. In the RAI-R-DTC trial, 14% had at least grade 3 QTc prolongation. The vandetanib prescribing instructions also note that fatal cases of Stevens-Johnson syndrome and interstitial lung disease have occurred with this agent. It should also be noted that the FDA package insert for pazopanib indicates QT prolongation in ,2% patients, and QT monitoring should be performed.
Sunitinib is contraindicated in patients with clinical congestive heart failure because the drug is associated with decline in ejection fraction, as observed in RCC, GI stromal tumor, and pancreatic neuroendocrine tumor trials. These trials excluded patients with cardiac events within the prior year from treatment, thus caution is advised in this setting, including baseline and periodic monitoring of left ventricular ejection fraction. Sunitinib also prolongs QT interval in a dosedependent manner, and monitoring should be considered.
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The Oncologist ® 120 TKIs in RAI-Refractory Thyroid Cancer CME A number of studies have looked at sequencing of TKI administration or the use of TKIs in the second-line setting for RAI-refractory DTC in patients whose cancers have progressed while receiving first-line TKIs. In summary, these data seem to suggest that a second-line TKI can be as effective as TKI in the first-line setting regardless of the sequence.
Although an agent with alternate molecular targets could be considered, the data do not suggest this is more efficacious than a TKI with similar molecular targets. Dadu et al. studied salvage TKI use after sorafenib failure in a retrospective analysis of 60 patients with metastatic RAI-refractory DTC [119] . Patients treated with sorafenib only and not offered a second-line TKI had OS of 24 months, whereas patients offered a second-line TKI had significantly improved overall survival of 63 months; however, in the second-line setting after sorafenib, treatment with sunitinib, pazopanib, cabozantinib, lenvatinib, or vemurafenib seemed to have equivalent effects on prolonging outcomes. Notably, in the second-line setting, there was actually a higher partial response rate of 41%, and 59% achieved stable disease. It is unclear whether this outcome represents differences in activity compared with sorafenib or other biological or patient-related factors. Similarly, Massicotte et al. studied 62 patients with RAIrefractory DTC treated with a number of agents including sorafenib and sunitinib. In the first-line setting, these agents were associated with a 36% partial response rate by RECIST 1.1 and PFS of 6.7 months [120] . When used interchangeably in the second line, no partial responses were seen; however, progression-free survival was essentially the same at 7.6 months, suggesting that sequencing of the agents was not important.
One study suggested that patients with BRAF V600E mutations may benefit from first-line BRAF-targeted agents rather than other TKIs [80] . This phase II study enrolled 51 patients with RAI-R-DTC that harbored BRAF V600E mutations and treated them with vemurafenib. Patients were stratified by prior TKI exposure.TKI-naïve patients had a better response rate and PFS (35% and 15.6 months) compared with patients previously treated with TKI (25% and 6.8 months). Eighty-five percent of the patients previously treated with TKI had received sorafenib. Further studies will be needed to confirm whether vemurafenib in the first-line setting is truly superior to the second-line setting and whether the choice of first-line agent makes any difference.
INDUCING RAI UPTAKE IN RAI-R-DTC
Strategies to improve RAI uptake in RAI-refractory DTC have been explored recently. At the 2013 ASCO annual meeting, Rothberg et al. presented a study of seven patients with BRAFmutant RAI-R-DTC treated with dabrafenib to induce iodine uptake on whole-body scan [121] . There were five evaluable patients, of which three had induced RAI uptake and went on to receive radioactive iodine treatment. All three also had increased thyroglobulin levels, suggesting redifferentiation in response to dabrafenib.
The MEK1/2 inhibitor selumetinib has also been evaluated for redifferentiation properties by PET scan in RAI-refractory metastatic DTC [69] . Twenty patients were evaluated, eight received radioactive iodine therapy on the basis of PET scan, and five of those had NRAS mutations. Of eight treated patients, five had confirmed partial response and three had stable disease. One patient developed myelodysplastic syndrome that progressed to leukemia approximately 1 year after treatment, possibly highlighting the limitations of repeated RAI administrations.
DISCUSSION
The treatment of RAI-R-DTC is undergoing transformation.The number of agents with demonstrable anticancer activity has progressed from none to eight in the past 5 years and is expected to rise in coming years. Only sorafenib is FDA approved for RAI-R-DTCtreatment; however, a number ofother agents are on the market forother indications and should be considered for the treatment of this disease. Lenvatinib appears to be the most active agent but is not yet available, with a PFS versus placebo triple that of sorafenib and a RECIST response rate five times that of sorafenib in the phase III setting.
The present level of evidence does not support testing for the presence of specific tumor mutations to guide therapy. Low-level evidence shows that presence of a RAS mutation may portend a more aggressive clinical course. Given the specificity of the BRAF-targeted agents vemurafenib and dabrafenib, use of these agents should be restricted to tumors that harbor BRAF V600E mutations. Presently, data are insufficient to suggest routine testing for this mutation, at least in the first-line setting. Knowledge of a BRAF mutation may be useful in the second-or third-line setting or if patients have contraindications to an antiangiogenic TKI, as discussed more fully below.
An importantconsiderationisthe propertiming for initiating TKI therapy in patients with RAI-R-DTC. Because of the lack of survival data and the relatively indolent nature of DTC, the rationale for treatment and the expected treatment endpoints should be conceptualized clearly. Because DTC is an indolent disease, it is important to document that the disease is actually progressing when considering therapy and that progression is causing symptoms or is anticipated to cause symptoms shortly. Many of the trials discussed required evidence of progression as documented on interval cross-sectional imaging within the prior year or 6 months as an entry criterion. The concept is that documentation of RAI-refractory disease is not enough to merit treatment with TKIs in the absence of more robust data indicating that doing so will alter an important patient-related outcome. The worry is that because TKIs are life-long, chronic treatments, patients will be exposed to toxic drugs for a protracted period without meaningful clinical benefit, especially because stable disease is often the most likely treatment outcome. The results of the DECISION trial with sorafenib can beinterpreted as demonstratingthatthere was no benefit to starting sorafenib earlier versus later, given that crossover was allowed and no difference in median OS was observed. In addition, quality of life evaluation suggested that patients receiving sorafenib had worse quality of life than patients on placebo. TKIs must be balanced with the use of localized treatments including radiation, cryoablation, and embolization in the proper clinical setting.
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TKIs in RAI-Refractory Thyroid Cancer CME Once the decision to treat has been made, both efficacy and toxicity should be considered in choosing a first-line agent in RAI-R-DTC. Agents commercially available for the first-line setting include axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, and vandetanib. The selective BRAF inhibitors vemurafenib and dabrafenib are also available and could be considered in the first-line setting, especially for patients at risk of TKI-related side effects, such as GI perforation, tracheoesophageal fistula, or other antiangiogenic side effects. We eagerly await approval of lenvatinib, which, based on the SELECT trial, greatly prolongs PFS compared with placebo; SELECT is the first trial to demonstrate PR rates by RECIST in .60% of patients.
Regarding efficacy, no OS data exists to guide us; however, PFS rates are generally similar, at ∼1 year with all agents. A possible exception is increased PFS with axitinib and lenvatinib, although the axitinib trials did not specifically enroll patients with documented progressive disease. Pazopanib and lenvatinib have higher response rates of ∼50% compared with 20%-40% with other agents.This indicates that if achieving a response is an important treatment objective, pazopanib (or lenvatinib, when available) may be the best choice. A patient with a symptomatic mass, for example, would benefit from treatment to shrink disease, improve symptoms, and improve quality of life.
Toxicity is an equally important consideration, and many agents have side-effect profiles that may limit use. Patients with cardiac issues will need careful consideration before treatment with vandetanib or sunitinib because of the risks of QT prolongation/sudden death and coronary heart failure, respectively. Patients with pre-existing liver disease would not be good candidates for pazopanib or sunitinib. Patients should be counseled about the prevalence of dermatologic toxicities; the hypopigmentation associated with pazopanib may be unacceptable to certain patients. Patients with propensity for bleeding or GI perforation may not be good candidates for TKI therapy in general, and BRAF inhibitors could be considered for first line in this setting if their disease harbors a BRAF V600E mutation. Patients with large invasive neck masses or prior neck radiation may be predisposed to tracheoesophageal fistula, thus antiangiogenic TKIs should be used judiciously in this setting.
At the current time, no overwhelming data strongly support the first-line selection of one agent over another. This may change when lenvatinib is approved. At the current time, we recommend individualized selection based on the intent of therapy, the expected side-effect profile, and patient input. Practically, FDA approval of sorafenib for RAI-R-DTC may make this agent the most appropriate first-line therapy in the near term, especially when considering the likelihood of insurance authorization. Axitinib or pazopanib are equally good choices in the first-line setting because of their efficacy and relatively tolerable side-effect profiles.
Data are currently insufficient to suggest that switching to an agent that inhibits a novel target in the second line will be any more effective than an agent of similar class. In the secondline setting after TKI, for example, the presence of a BRAF V600E mutation may suggest switching to a BRAF inhibitor; however, this is not supported by current data. Further trials need to be performed before recommendations can be made in the second-line setting in RAI-R-DTC.
Data are currently insufficient to suggest that switching to an agent that inhibits a novel target in the second line will be any more effective than an agent of similar class.
In coming years, we can expect that more TKIs will progress toward approval for RAI-R-DTC. We also expect mTOR inhibitors and BRAF inhibitors may follow suit. Further questions to address in clinical trials involve the specific sequencing of agents and whether molecular characterization of tumor mutations is predictive of response, especially with the mTOR-and BRAF-targeted classes. In metastatic melanoma, MEK inhibitors have single-agent activity similar to BRAF inhibitors, and combined MEK/BRAF inhibition leads to improved PFS and response rates with decreased dermatologic toxicity [122, 123] .We hypothesize that the same might be true for DTC. In RAI-R-DTC, efforts thus far have been channeled toward improving RAI uptake with MEK inhibition, which appears feasible; however, it is possible that MEK inhibitor treatment may be effective in itself, without giving RAI. In other words, improving iodine uptake may be a marker of more indolent biology and may be a desirable outcome in itself, even if RAI is not given. An open phase II trial is evaluating the selective BRAF inhibitor dabrafenib with or without the MEK inhibitor trametinib in DTC (NCT01723202). More generally, combinations of targeted agents are a largely unexplored area that deserves further study.
CONCLUSION
Patients with RAI-R-DTC have an expanding suite of drugs available and in the pipeline that hold clinical promise. Selection of a targeted agent should depend on careful documentation of the patient's disease trajectory, consideration of side-effect profile, and realistic discussion of the goals of therapy. 
